|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
The angiopoietin-like proteins (ANGPTLs), consisting of ANGPTL3, ANGPTL4, and ANGPTL8, have gained significant interest for their role as inhibitors of lipoprotein lipase (LPL) and for their potential as therapeutic targets for correcting dyslipidemia.
|
30893111 |
2019 |
|
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Reduced lipoprotein lipase activity, increased very low-density lipoprotein production, increased proprotein convertase subtilisin kexin type 9 (PCSK9) expression and loss of hepatic heparan sulfate proteoglycans (HSPG) syndecan-1 have been associated with CKD-related dyslipidemia.
|
30550765 |
2019 |
|
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
BEFREE |
However, dyslipidemia-especially elevated low-density lipoprotein (LDL-c) and triglyceride levels, as well as reduced lipoprotein lipase activity-is associated with an increased risk of coronary artery disease (CAD).
|
31227920 |
2019 |
|
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Although several epidemiological studies have shown that hepatic low lipoprotein lipase (LPL) mRNA expression may be associated with dyslipidemia and tumor progression, it is still not known whether the liver plays an essential role in hyperlipidemia of Apc<sup>Min/+</sup> mice.
|
31002917 |
2019 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Among genetic factors that contributed to incidence of metabolic syndrome, Polymorphisms of Lipoprotein lipase (LPL) are major candidates especially because of their effect on obesity and dyslipidemia.
|
31034941 |
2019 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
The present results suggest that paeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice.
|
30096295 |
2018 |
|
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Evidence is now emerging that volanesorsen, a second-generation antisense oligonucleotide drug targeting ApoCIII messenger RNA resulting in decreases in TG in patients with familial chylomicronemia syndrome, severe hypertriglyceridemia, and metabolic dyslipidemia with type 2 diabetes giving support to the hypothesis that ApoCIII is a powerful inhibitor of LPL, and when reduced, endogenous clearance of TRLs can result in substantial reductions in TG levels.
|
29124482 |
2017 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
The data suggests that ANGPTL3 is part of the machinery causing dyslipidemia majorily via LPL inhibition in mastitis mice.
|
29104012 |
2017 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Our findings indicate that, in well characterized FCHL individuals, variants in LDLR and LPL provide a small contribution to this dyslipidemia, thus limiting the need for such genetic testing.
|
26342331 |
2015 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In individuals with mixed dyslipidemia rare synonymous variants within LPL gene were associated with attenuated response to FA therapy while APOCIII rare variants were associated with a modest effect on APOB response to FA-statin therapy.
|
24704626 |
2014 |
|
Dyslipidemias
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
CETP and LPL DNA methylation levels are associated with blood lipid profile, suggesting that further studies of epipolymorphisms should most certainly contribute to a better understanding of the molecular bases of dyslipidemia.
|
23623643 |
2013 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
|
22236405 |
2012 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Lipoprotein lipase (LPL) is a key enzyme in lipid metabolism and is associated with obesity, dyslipidemias, hypertension (HTN) and type 2 diabetes mellitus (T2DM).
|
23089926 |
2012 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In conclusion, the LPL gene +495T > G and PvuII T > C polymorphisms may modulate the magnitude of dyslipidemia in Chinese early-onset obesity.
|
21431783 |
2011 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Co-expression of apoE4[R142C] with lecithin cholesterol acyltransferase (LCAT) or lipoprotein lipase (LPL) in apoE(-/-) mice partially corrected the apoE4[R142C]-induced dyslipidemia.
|
20861163 |
2011 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Evidence from these studies indicate that LPL dysfunction is involved in dyslipidemia, T2D, EH, CHD and AD; and support the hypothesis that there is a common or shared biological basis for these common complex diseases.
|
19639021 |
2010 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
However, the role of LPL gene T+195G polymorphism in central obesity and dyslipidemia is complex and remains controversial.
|
18693040 |
2008 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The contribution to dyslipidemia of 20 selected single nucleotide polymorphisms of 13 genes reported in the literature to be associated with plasma lipid levels (ABCA1, ADRB2, APOA5, APOC3, APOE, CETP, LIPC, LIPG, LPL, MDR1, MTP, SCARB1, and TNF) was assessed by longitudinally modeling more than 4400 plasma lipid determinations in 438 antiretroviral therapy-treated participants during a median period of 4.8 years.
|
17700364 |
2007 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
CTD_human |
Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol.
|
17952847 |
2007 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
And the Asn291Ser variant in the LPL gene predisposes to more severe dyslipidemia with increasing age and weight gain.
|
16741292 |
2006 |
|
Dyslipidemias
|
0.400 |
AlteredExpression
|
group |
LHGDN |
To evaluate the influence of cholesterol ester transfer protein (CETP) TaqIB polymorphism, lipoprotein lipase (LPL) PvuII and HindIII polymorphisms, hepatic lipase (LIPC) G-250A polymorphism and apolipoprotein C-III (APOC3) SstI gene polymorphism on lipid levels in dyslipidemia of the metabolic syndrome, 150 patients with dyslipidemia of metabolic syndrome were included.96 % of patients had type 2 diabetes.
|
16343038 |
2006 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
IM application of AAV1-LPL(S447X) is effective in reducing TG levels in a mouse model for type III dyslipidemia.
|
16990047 |
2006 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To evaluate the influence of cholesterol ester transfer protein (CETP) TaqIB polymorphism, lipoprotein lipase (LPL) PvuII and HindIII polymorphisms, hepatic lipase (LIPC) G-250A polymorphism and apolipoprotein C-III (APOC3) SstI gene polymorphism on lipid levels in dyslipidemia of the metabolic syndrome, 150 patients with dyslipidemia of metabolic syndrome were included.96 % of patients had type 2 diabetes.
|
16343038 |
2006 |
|
Dyslipidemias
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to investigate the association between the common lipoprotein lipase HindIII (T-G) and Ser447Ter (C-G) polymorphisms with dyslipidemia in Asian Indians, who are known to have very high rates of premature coronary artery disease.
|
16635607 |
2006 |
|
Dyslipidemias
|
0.400 |
Biomarker
|
group |
BEFREE |
Such findings support the active role of placental LPL and APOE in the metabolism of maternal lipoproteins and suggest that fetal genes may modulate the risk for problems related to maternal dyslipidemia (preeclampsia, pancreatitis, and future cardiovascular disease).
|
16106048 |
2005 |